Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
View Patent ↗The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.
1. A pharmaceutical composition comprising a therapeutically effective amount to treat acute post-operative pain or chronic inflammatory pain of:
a) a first pharmacologically active ingredient, which is selected from the compound according to formula (I)
and the physiologically acceptable salts thereof, and
b) a second pharmacologically active ingredient, which is ibuprofen or a physiologically acceptable salt thereof, wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of 1:30 to 1:1,000,000.
2. The pharmaceutical composition according to claim 1 , wherein the first pharmacologically active ingredient is (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine.
3. A pharmaceutical dosage form comprising the pharmaceutical composition according to claim 1 .
4. The pharmaceutical dosage form according to claim 3 , which contains the first pharmacologically active ingredient in a dose of 10 to 1,200μg.
5. The pharmaceutical dosage form according to claim 3 , which contains the second pharmacologically active ingredient in a dose of 0.05 to 5 g.
6. The pharmaceutical dosage form according to claim 3 , wherein the dosage of the first pharmacologically active ingredient is within the range of 1:20 to 20:1 of the amount which is equieffective to the dosage of the second pharmacologically active ingredient.
7. The pharmaceutical dosage form according to claim 3 , which is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration.
8. The pharmaceutical dosage form according to claim 3 , which provides under in vitro conditions immediate release or controlled release of the first pharmacologically active ingredient, the second pharmacologically active ingredient, or both.
9. A kit comprising a first pharmaceutical dosage form comprising the first pharmacologically active ingredient as defined in claim 1 , a second pharmaceutical dosage form comprising the second pharmacologically active ingredient as defined in claim 1 , and packaging.
10. The kit according to claim 9 , wherein the first pharmaceutical dosage form and the second pharmaceutical dosage form are adapted for simultaneous or sequential administration, either by the same or a different pathway of administration.
11. A method of treating acute post-operative pain or chronic inflammatory pain, comprising administering a pharmaceutical dosage form comprising a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a therapeutically effective amount to treat acute post-operative pain or chronic inflammatory pain of:
a) a first pharmacologically active ingredient, which is selected from the compound according to formula (I)
and the physiologically acceptable salts thereof, and
b) a second pharmacologically active ingredient, which is ibuprofen or a physiologically acceptable salt thereof, wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of 1:30 to 1:1,000,000.
12. The method according to claim 11 , wherein the acute post-operative pain or the chronic inflammatory pain is peripheral pain, central pain, or muscle skeletal pain.
13. The method according to claim 11 , wherein the acute post-operative pain or the chronic inflammatory pain is moderate to severe pain.
14. The method according to claim 11 , wherein the acute post-operative pain or the chronic inflammatory pain is neuropathic pain, psychogenic pain, nociceptive pain, or mixed pain.
15. The method according to claim 11 , wherein the acute post-operative pain or the chronic inflammatory pain is low back pain, visceral pain, or headache.
16. The method according to claim 11 , wherein the first pharmacologically active ingredient is (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4b]-indol]-4-amine.
17. The method according to claim 11 , wherein the pharmaceutical composition contains the first pharmacologically active ingredient and the second pharmacologically active ingredient in such a weight ratio that they will exert a synergistic therapeutic effect upon administration to a patient.
18. The method according to claim 11 , wherein the pharmaceutical dosage form contains the first pharmacologically active ingredient in a dose of 10 to 1,200 μg.
19. The method according to claim 11 , wherein the pharmaceutical dosage form contains the second pharmacologically active ingredient in a dose of 0.05 to 5 g.
20. The method according to claim 11 , wherein, in the pharmaceutical dosage form, the dosage of the first pharmacologically active ingredient is within the range of 1:20 to 20:1 of the amount which is equieffective to the dosage of the second pharmacologically active ingredient.
21. The method according to claim 11 , wherein the pharmaceutical dosage form is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration.
22. The method according to claim 11 , wherein the pharmaceutical dosage form provides under in vitro conditions immediate release or controlled release of the first pharmacologically active ingredient, the second pharmacologically active ingredient, or both.
23. A pharmaceutical composition comprising a therapeutically effective amount to treat acute post-operative pain or chronic inflammatory pain of:
a) a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and
b) a second pharmacologically active ingredient, which is ibuprofen or a physiologically acceptable salt thereof,
wherein the first pharmacologically active ingredient and the second pharmacologically active ingredient are present in such a weight ratio that they will exert a synergistic therapeutic effect upon administration to a patient.